Previous 10 | Next 10 |
Reata Pharmaceuticals is up 183% in Wednesday afternoon terading after the US FDA on Tuesday approved the company's Friedreich's ataxia drug Skyclarys (omaveloxolone). The treatment comes with an annual list price of $330K. Skyclarys is the first drug approved for the rare mo...
Gainers: Reata Pharmaceuticals ( RETA ) +175% . OncoSec Medical ( ONCS ) +94% . B&G Foods ( BGS ) +30% . Nerdy ( NRDY ) +29% . SCYNEXIS ( SCYX ) +29% . Blackboxstocks ( BLBX ) +29% . Red Robin Gourmet Burgers ( RRGB ...
Gainers: Reata Pharmaceuticals ( RETA ) +176% . OncoSec Medical ( ONCS ) +118% . Sarepta Therapeutics ( SRPT ) +24% . PetIQ ( PETQ ) +17% . Amphastar Pharmaceuticals ( AMPH ) +15% . Losers: Novavax ( NVAX ) -24% . ...
The stock market finished the month of February lower, giving back some of its gains from January. However, as investors prepared for the first day of March, the Nasdaq Composite (NASDAQINDEX: ^IXIC) tried to rebound, with gains of about 0.2% in futures trading before the market opened We...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: benjamin poturak / Shutterstock.com Novavax (NASDAQ: NVAX ) stock is dropping on Wednesday after the vaccine company warned investors about the state of its business. In its latest earnings report, Novavax...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock OKYO Pharma (NASDAQ: OKYO ) stock is taking a beating on Wednesday despite recent progress toward a clinical trial . The latest news from OKYO Pharma is that its GMP-packaged OK-101 drug for ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock OncoSec Medical (NASDAQ: ONCS ) stock is rising higher on Wednesday after the company withdrew a public stock offering . According to the company, it no longer wants to move forward with the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Reata Pharmaceuticals (NASDAQ: RETA ) stock is rocketing higher on Wednesday following approval from the FDA for one of its drugs. The FDA approval covers the use of the c...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com It’s time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! Moving stocks this morning are a U.S. Food a...
The US FDA has approved Reata Pharmaceuticals' ( NASDAQ: RETA ) Friedreich's ataxia treatment omaveloxolone. Branded as Skyclarys, the drug is approved for those 16 years and older with the inherited neuronal disorder. The approval is the first FDA-approved therapy for t...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...